This Month’s Focus: Particle Characterization
Cascade impactor stage groupings: Poor decisions from degraded data
The second in a series of articles from the IPAC-RS Cascade Impaction Working Group concerning the limitations of metrics commonly used in the assessment of aerodynamic particle size distributions (APSDs) of orally inhaled products (OIPs). This article explores the limitations of stage groupings, probing whether they are suitable for making batch disposition decisions based on inhaler performance testing.
The liability of fine particle dose (FPD)
The first in a series of articles from the IPAC-RS Cascade Impaction Working Group concerning the limitations of metrics commonly used in the assessment of aerodynamic particle size distributions (APSDs) of orally inhaled products (OIPs). The current article discusses the surprisingly limited utility of the fine particle dose metric in quality control.
General Features
Particle engineering approaches for dry powder inhalers
Drug developers can use bottom-up or top-down particle engineering approaches or a combination. Selecting the best approach depends on characteristics of the active pharmaceutical ingredient and the target product profile, including the inhaled biopharmaceutical classification system of the drug in development.
Back Page: Use of antibiotics in infants correlates with allergies in children, though causation not shown
A study of nearly 800,000 children found that infants who were given antibiotics had an increased risk of developing allergies (such as food allergies), asthma or dermatitis as children. A causative relationship was not found and more research is needed to determine the nature of the association.
Cross-industry organizations: The Respiratory Drug Delivery Conferences: Digitally Augmented
A review of the transformation to Digital RDD 2020, due to COVID-19, and a summary of current plans for the RDD Conference Series in 2021
October Content
Development of HFA-152a as a sustainable pMDI propellant
Inhaled administration of drugs to animals in pharmaceutical research
Cross-industry organizations: Association of Inhalation Toxicologists
Issue Focuses
January: Reference and Buyer’s Resource
February: Product Development/ Contract Testing
April: Instruments
June: Nasal Delivery/Nebulizers
August: Particle Characterization
October: Devices
December: Quality/Compliance
Vicki Schuman
1155 Northland Drive
St. Paul, MN 55120
651-287-5600
Fax 651-287-5650
vschuman@cscpub.com
Inhalation Article Guidelines
Technical article requirements
The article should be technical and educational, but not promotional. It must be new, not previously published and must be at least 50% different from your previous articles or other articles you are simultaneously developing on the same subject.
All discussions of products or technologies must be in an unbiased, non-promotional, educational manner. If your article discusses products that have been commercialized or are in development, please be aware of the following: Inhalation takes a very limited approach in discussing products, usually listing only product name, delivered drug name and company name, unless a description is provided by the particular company that owns a product, such as in a case study article or product news release. In that way, each company can choose the information it wishes to discuss or disclose about its own products, rather than being discussed by an outside party with no ability to comment prior to publication. However, if an article is a case study, presentation of a novel technology or news article written by the owner company or its representative such as a scientist or consultant, we are happy to consider all information or data they wish to disclose, provided it is presented in a fair-balanced manner. Also, please avoid discussing product or development costs and do not make cost comparisons.
The article should be 2,500-3,500 words and must include at least five references or items for recommended reading.
We encourage images and/or data tables and have space for three or four of them. We’re flexible about that number so let us know if you need more image space. We also like to publish an additional photo or illustration at the beginning of the article. Images should be sent as separate files that meet the following specifications: high resolution, 300 dpi at a size of 7 x 7 inches and in only JPG, TIF or EPS formats.
Please be aware, due to copyrights, if you use figures or tables from articles that have been previously published in other journals, you must obtain permission from those journals in order to use the images. If you are an author on the published article in question, you may still need permission but there should be no fees from the other journal. If you are not an author and the other journal wants to charge you fees for usage, please contact us before proceeding. We do not want authors incurring costs in order to publish in Inhalation and there may be alternate approaches to citing information that could be used. Also, “open journals” do not charge for image use. If you have any questions or concerns, please contact us.
Editorial board review and production
All of our articles are peer-reviewed and must be accepted by our editorial board or a designated reviewer in order to be published. When you send us the article, it will go to a member of the board and we will coordinate communication between you. Once an article is accepted, we handle production and you will see the final article in layout before it goes to print or is published in the digital edition.
Contract Testing
Excipients
